<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168815</url>
  </required_header>
  <id_info>
    <org_study_id>vSep2016</org_study_id>
    <nct_id>NCT03168815</nct_id>
  </id_info>
  <brief_title>Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy</brief_title>
  <official_title>Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mount Sinai Hospital, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pneumonia is a lung infection. Fiberoptic bronchoscopy is a test to diagnose the type of lung
      infection. While this procedure is being performed, a small amount of oxygen is delivered
      into the nose (low flow nasal cannula). Occasionally during this procedure, the blood oxygen
      of the patient may drop and an intervention such as increasing the oxygen flow, or placing
      the patient on a breathing machine is required. An alternative device called 'Optiflow' can
      provide high flow oxygen through nasal cannula, and is comfortable for patients. If Optiflow
      is used during bronchoscopy, it may prevent the blood oxygen from dropping.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pneumonia is a lung infection that is a common complication in people with cancer, because of
      a weak immune system. Fiberoptic bronchoscopy is a test that is commonly used to help doctors
      diagnose the type of lung infection and treat it appropriately. It involves passing a thin
      tube with a camera at the end inside the lungs, and taking some fluid samples which are sent
      for analysis. While this procedure is being performed, a small amount of oxygen is delivered
      into the nose (low flow nasal cannula). Occasionally during this procedure, the blood oxygen
      of the patient may drop (even if the patient is receiving oxygen, and especially if the
      patient has severe pneumonia), and the procedure may have to be interrupted or prematurely
      stopped. If the oxygen level drops significantly, an intervention such as increasing the
      oxygen flow, or in the worst-case scenario temporarily placing the patient on a breathing
      machine is required. An alternative device called 'Optiflow' can provide high flow oxygen
      through nasal cannula, and is comfortable for patients. Optiflow was approved by Health
      Canada in 2006, and is commonly used in hospitals in Ontario and around the world to support
      patients whose blood oxygen is low. If Optiflow is used during bronchoscopy, it may prevent
      the blood oxygen from dropping.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to either HFNC delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure; or to conventional supplemental LFNC delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Desaturation during FOB</measure>
    <time_frame>The SpO2 will be measured using a bedside SpO2 measuring device during or 1 hour post-FOB defined as a drop in SpO2 of 4% or more for &gt; 1 minute or any drop in O2 &lt;90% necessitating an increase in FiO2 to maintain a saturation ≥92% for at least 1 minute.</time_frame>
    <description>Any desaturation during FOB or during the 1 hour post-FOB defined as a drop in SpO2 of 4% or more for more than 1 minute or any drop in O2 less than 90%, and necessitating an increase in FiO2 to maintain a saturation ≥92% for at least 1 minute.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Immunocompromised</condition>
  <condition>Hematologic Malignancy</condition>
  <condition>Post Hematopoietic Stem Cell Transplant</condition>
  <condition>Hypoxia</condition>
  <condition>Pulmonary Infiltrates</condition>
  <arm_group>
    <arm_group_label>High Flow Nasal Cannula (HFNC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygen is delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Flow Nasal Cannula (LFNC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxygen is delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Flow Nasal Cannula or Low Flow Nasal Cannula</intervention_name>
    <description>HFNC vs LFNC</description>
    <arm_group_label>High Flow Nasal Cannula (HFNC)</arm_group_label>
    <arm_group_label>Low Flow Nasal Cannula (LFNC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients ≥18 years scheduled to undergo FOB (as determined by their medical care
             team) who are immunocompromised (active hematologic malignancy or post hematopoietic
             stem cell transplant), and are hypoxic with pulmonary infiltrates. Hypoxia will be
             defined as requiring supplemental low flow oxygen ≥ 2L/min by nasal cannula to
             maintain SpO2 &gt;90%.

        Exclusion Criteria:

          1. requiring supplemental oxygen &gt; 8L/min by nasal cannula;

          2. receiving HFNC before randomization;

          3. nasal deformity or packing precluding HFNC use;

          4. hypercapnia (PaCO2 &gt; 60) or respiratory acidosis (pH &lt;7.25);

          5. requiring NIV for over 1 hour or intubated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Sangeeta Mehta, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Sangeeta Mehta, MD, FRCPC</last_name>
    <phone>416-586-4800</phone>
    <phone_ext>4604</phone_ext>
    <email>geeta.mehta@utoronto.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr. Laveena Munshi, MD, FRCPC</last_name>
    <phone>416-586-4800</phone>
    <phone_ext>6571</phone_ext>
    <email>Laveena.Munshi@sinaihealthsystem.ca</email>
  </overall_contact_backup>
  <reference>
    <citation>Hummel M, Rudert S, Hof H, Hehlmann R, Buchheidt D. Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates. Ann Hematol. 2008 Apr;87(4):291-7. Epub 2007 Oct 12.</citation>
    <PMID>17932672</PMID>
  </reference>
  <reference>
    <citation>Shannon VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DP. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Apr;45(4):647-55. doi: 10.1038/bmt.2009.203. Epub 2009 Aug 17.</citation>
    <PMID>19684637</PMID>
  </reference>
  <reference>
    <citation>Kuehnhardt D, Hannemann M, Schmidt B, Heider U, Possinger K, Eucker J. Therapeutic implication of BAL in patients with neutropenia. Ann Hematol. 2009 Dec;88(12):1249-56. doi: 10.1007/s00277-009-0747-1. Epub 2009 May 5.</citation>
    <PMID>19415277</PMID>
  </reference>
  <reference>
    <citation>Hohenadel IA, Kiworr M, Genitsariotis R, Zeidler D, Lorenz J. Role of bronchoalveolar lavage in immunocompromised patients with pneumonia treated with a broad spectrum antibiotic and antifungal regimen. Thorax. 2001 Feb;56(2):115-20.</citation>
    <PMID>11209099</PMID>
  </reference>
  <reference>
    <citation>Goldstein RA, Rohatgi PK, Bergofsky EH, Block ER, Daniele RP, Dantzker DR, Davis GS, Hunninghake GW, King TE Jr, Metzger WJ, et al. Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis. 1990 Aug;142(2):481-6. Review.</citation>
    <PMID>2200319</PMID>
  </reference>
  <reference>
    <citation>Matsushima Y, Jones RL, King EG, Moysa G, Alton JD. Alterations in pulmonary mechanics and gas exchange during routine fiberoptic bronchoscopy. Chest. 1984 Aug;86(2):184-8.</citation>
    <PMID>6744959</PMID>
  </reference>
  <reference>
    <citation>Schnabel RM, van der Velden K, Osinski A, Rohde G, Roekaerts PM, Bergmans DC. Clinical course and complications following diagnostic bronchoalveolar lavage in critically ill mechanically ventilated patients. BMC Pulm Med. 2015 Sep 29;15:107. doi: 10.1186/s12890-015-0104-1.</citation>
    <PMID>26420333</PMID>
  </reference>
  <reference>
    <citation>Maitre B, Jaber S, Maggiore SM, Bergot E, Richard JC, Bakthiari H, Housset B, Boussignac G, Brochard L. Continuous positive airway pressure during fiberoptic bronchoscopy in hypoxemic patients. A randomized double-blind study using a new device. Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):1063-7.</citation>
    <PMID>10988131</PMID>
  </reference>
  <reference>
    <citation>Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E, Cottereau A, Devaquet J, Nseir S, Razazi K, Mira JP, Argaud L, Chakarian JC, Ricard JD, Wittebole X, Chevalier S, Herbland A, Fartoukh M, Constantin JM, Tonnelier JM, Pierrot M, Mathonnet A, Béduneau G, Delétage-Métreau C, Richard JC, Brochard L, Robert R; FLORALI Study Group; REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015 Jun 4;372(23):2185-96. doi: 10.1056/NEJMoa1503326. Epub 2015 May 17.</citation>
    <PMID>25981908</PMID>
  </reference>
  <reference>
    <citation>Frat JP, Ragot S, Girault C, Perbet S, Prat G, Boulain T, Demoule A, Ricard JD, Coudroy R, Robert R, Mercat A, Brochard L, Thille AW; REVA network. Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial. Lancet Respir Med. 2016 Aug;4(8):646-652. doi: 10.1016/S2213-2600(16)30093-5. Epub 2016 May 27.</citation>
    <PMID>27245914</PMID>
  </reference>
  <reference>
    <citation>Nishimura M. High-flow nasal cannula oxygen therapy in adults. J Intensive Care. 2015 Mar 31;3(1):15. doi: 10.1186/s40560-015-0084-5. eCollection 2015. Review.</citation>
    <PMID>25866645</PMID>
  </reference>
  <reference>
    <citation>Lomas C, Roca O, Alvarez A, et al. Fibroscopy in patients with hypoxemic respiratory insufficiency: Utility of the high-flow nasal cannula. Respiratory Medicine CME 2009;2:121.</citation>
  </reference>
  <reference>
    <citation>Diab S, Fraser JF. Maintaining Oxygenation Successfully with High Flow Nasal Cannula during Diagnostic Bronchoscopy on a Postoperative Lung Transplant Patient in the Intensive Care. Case Rep Crit Care. 2014;2014:198262. doi: 10.1155/2014/198262. Epub 2014 Nov 13.</citation>
    <PMID>25478241</PMID>
  </reference>
  <reference>
    <citation>Miyagi K, Haranaga S, Higa F, Tateyama M, Fujita J. Implementation of bronchoalveolar lavage using a high-flow nasal cannula in five cases of acute respiratory failure. Respir Investig. 2014 Sep;52(5):310-4. doi: 10.1016/j.resinv.2014.06.006. Epub 2014 Jul 25.</citation>
    <PMID>25169847</PMID>
  </reference>
  <reference>
    <citation>16. Kim KC, Hyun DS. Usefulness of high-flow nasal cannula (HFNC) oxygen delivery during bronchoalveolar lavage (BAL) in spontaneous breathing patients with hypoxemia. European Respiratory Journal. 2014; 44: p706.</citation>
  </reference>
  <reference>
    <citation>Lucangelo U, Vassallo FG, Marras E, Ferluga M, Beziza E, Comuzzi L, Berlot G, Zin WA. High-flow nasal interface improves oxygenation in patients undergoing bronchoscopy. Crit Care Res Pract. 2012;2012:506382. doi: 10.1155/2012/506382. Epub 2012 May 20.</citation>
    <PMID>22666567</PMID>
  </reference>
  <reference>
    <citation>Simon M, Braune S, Frings D, Wiontzek AK, Klose H, Kluge S. High-flow nasal cannula oxygen versus non-invasive ventilation in patients with acute hypoxaemic respiratory failure undergoing flexible bronchoscopy--a prospective randomised trial. Crit Care. 2014 Dec 22;18(6):712. doi: 10.1186/s13054-014-0712-9.</citation>
    <PMID>25529351</PMID>
  </reference>
  <reference>
    <citation>Parke R, McGuinness S, Eccleston M. Nasal high-flow therapy delivers low level positive airway pressure. Br J Anaesth. 2009 Dec;103(6):886-90. doi: 10.1093/bja/aep280. Epub 2009 Oct 20.</citation>
    <PMID>19846404</PMID>
  </reference>
  <reference>
    <citation>Antonelli M, Conti G, Rocco M, Arcangeli A, Cavaliere F, Proietti R, Meduri GU. Noninvasive positive-pressure ventilation vs. conventional oxygen supplementation in hypoxemic patients undergoing diagnostic bronchoscopy. Chest. 2002 Apr;121(4):1149-54.</citation>
    <PMID>11948045</PMID>
  </reference>
  <reference>
    <citation>La Combe B, Messika J, Labbé V, Razazi K, Maitre B, Sztrymf B, Dreyfuss D, Fartoukh M, Ricard JD. High-flow nasal oxygen for bronchoalveolar lavage in acute respiratory failure patients. Eur Respir J. 2016 Apr;47(4):1283-6. doi: 10.1183/13993003.01883-2015. Epub 2016 Feb 11.</citation>
    <PMID>26869676</PMID>
  </reference>
  <reference>
    <citation>Fang WF, Chen YC, Chung YH, Woon WT, Tseng CC, Chang HW, Lin MC. Predictors of oxygen desaturation in patients undergoing diagnostic bronchoscopy. Chang Gung Med J. 2006 May-Jun;29(3):306-12.</citation>
    <PMID>16924893</PMID>
  </reference>
  <reference>
    <citation>23. Chris Hau (respiratory therapist - Princess Margaret Hospital), Clodagh Ryan (Respirologist, Princess Margaret Hospital, Geeta Mehta (Respirologist, Princess Margaret Hospital) (personal communication, November 2016)</citation>
  </reference>
  <reference>
    <citation>Miguel-Montanes R, Hajage D, Messika J, Bertrand F, Gaudry S, Rafat C, Labbé V, Dufour N, Jean-Baptiste S, Bedet A, Dreyfuss D, Ricard JD. Use of high-flow nasal cannula oxygen therapy to prevent desaturation during tracheal intubation of intensive care patients with mild-to-moderate hypoxemia. Crit Care Med. 2015 Mar;43(3):574-83. doi: 10.1097/CCM.0000000000000743.</citation>
    <PMID>25479117</PMID>
  </reference>
  <reference>
    <citation>La Combe B, Messika J, Fartoukh M, Ricard JD. Increased use of high-flow nasal oxygen during bronchoscopy. Eur Respir J. 2016 Aug;48(2):590-2. doi: 10.1183/13993003.00565-2016.</citation>
    <PMID>27478191</PMID>
  </reference>
  <reference>
    <citation>Santos PS, Cruz C, Esquinas AM. Increased use of high-flow nasal oxygen during bronchoscopy. Eur Respir J. 2016 Aug;48(2):589. doi: 10.1183/13993003.00441-2016.</citation>
    <PMID>27478190</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mount Sinai Hospital, Canada</investigator_affiliation>
    <investigator_full_name>Sangeeta Mehta</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HFNC</keyword>
  <keyword>Bronchoscopy</keyword>
  <keyword>Hypoxia</keyword>
  <keyword>Immunocompromised</keyword>
  <keyword>Hematological malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

